Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Melanoma 15Neoplasms 7Colorectal Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Ovarian Neoplasms 4Solid Tumors 3Urinary Bladder Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Thoracic Neoplasms 1Solid Tumor 1Skin Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Pancreatic Neoplasms 1Pancreatic Adenocarcinoma 1Noonan Syndrome 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms by Site 1Neoplasm Metastasis 1Multiple Myeloma 1Microsatellite Unstable Colorectal Cancer 1Lung Neoplasms 1Lung Diseases 1Leukemia, Myeloid, Acute 1Hereditary Sensory and Autonomic Neuropathies 1Glioblastoma 1Gastrointestinal Neoplasms 1

Interventions

lenvatinib 9vandetanib 5pembrolizumab 4Sorafenib 4selpercatinib 3Thyrotropin Alfa 3trametinib 2fosbretabulin 2combretastatin 2cabozantinib 2belinostat 2Paclitaxel 2Gemcitabine 2Fluorouracil 2Cetuximab 2Carboplatin 2Axitinib 2130-nm albumin-bound paclitaxel 2ulixertinib 1trastuzumab deruxtecan 1tipifarnib 1surufatinib 1repotrectinib 1pralsetinib 1naporafenib 1motesanib diphosphate 1methyl N-acetylsibirosaminide 1larotrectinib 1irofulven 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Thyroid Neoplasms × cobimetinib × Clear all
NCT04190628 2024-05-21

Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors

ABM Therapeutics Corporation

Phase 1 Terminated
53 enrolled
CNSDermatologicGastrointestinalGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Glioblastoma, Melanoma, Ovarian Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡